Posts tagged oral
Stifel downgrades Ocera Therapeutics to hold

Stifel downgraded Ocera Therapeutics (NASDAQ:OCRX) to “hold” from “buy” and slashed its price target to $1 from $9 after the company reported top-line results from a Phase 2b study evaluating ornithine phenylacetate (OCR-002) in hospitalized patients with hepatic encephalopathy (HE).

Read More
Vital Therapies updates Phase 3 trial

Vital Therapies (NASDAQ:VTL) updated its Phase 3 trial, VTL-308, designed to evaluate the ELAD System in subjects with severe acute alcoholic hepatitis.

Read More
Braeburn files for $150-million IPO

Closely held Braeburn Pharmaceuticals filed with U.S. regulators to raise up to $150-million in an initial public offering, seven months after its Probuphine implant to treat opioid addiction was approved by the FDA.

Read More
Arbutus, Spring Bank in HBV collaboration

Arbutus Biopharma (NASDAQ:ABUS) and Spring Bank Pharmaceuticals (NASDAQ:SBPH) agreed to perform collaborative preclinical studies in chronic Hepatitis B virus (HBV).

Read More
Leerink starts Aclaris at OP

Leerink initiated coverage of Aclaris Therapeutics (NASDAQ:ACRS) with an “outperform” rating and $54 price target. The stock closed at $28.04 on Monday.

Read More
Ladenburg upgrades Repros Therapeutics to buy

Ladenburg Thalmann upgraded Repros Therapeutics (NASDAQ:RPRX) to “buy” from “neutral,” with a new price target of $5.50. The stock closed at $1.93 on Wednesday.

In a new report, analyst Matthew Kaplan writes that Repros has announced positive Phase 2b data for both its oral and vaginal delivery trials, following two, 18-week cycles of treatment with Proellex for the treatment of uterine fibroids.

Read More
Oramed names Dr. Roy Eldor as CMD

Oramed Pharmaceuticals (NASDAQ:ORMP) appointed Dr. Roy Eldor to the newly created post of chief medical director.

“We are very pleased to welcome Dr. Eldor on board at this pivotal time for Oramed as we head towards a Phase 3 trial for our oral insulin capsule, ORMD-0801,” CEO, Nadav Kidron, said in a statement.

Read More
HCW starts Aviragen Therapeutics at buy

H.C. Wainwright launched coverage of Aviragen Therapeutics (NASDAQ:AVIR) with a “buy” rating and price target of $5. The stock closed at $1.43 on Tuesday.

Aviragen is a developing three direct-acting antiviral (DAA) compounds, each in Phase 2 development, including oral vapendavir, which targets human rhinovirus (HRV), causing the common cold; oral BTA585, which targets respiratory syncytial virus; and BTA074, which is a topical targeting human papillomavirus for condyloma.

Read More
Buprenorphine patient limit raised to 275

The Obama Administration will raise to 275 from 100 the limit on the number of patients with opioid addiction that certain physicians can treat with buprenorphine.

The move was part of several announced by the administration as part of an effort to stem the opioid abuse epidemic that is killing nearly 80 people from overdoses every day.

Read More
WB ups ARIAD price target to $12

William Blair has raised it price target for ARIAD Pharmaceuticals (NASDAQ:ARIA) to $12 from $10 after an analyst day on Friday where the company discussed the outcome of its strategic review. The stock was quoted at $7.59 on Monday afternoon.

The strategic review included ARIAD’s commitment to financial discipline and its refined focus on rare cancers with precision medicines in Iclusig, brigatinib, and AP32788, as well as discovery work on a suite of oral agents in immuno-oncology.

Read More
Roth reinitiates coverage of Cempra at buy

Roth Capital Partners has reinitiated coverage of Cempra (NASDAQ:CEMP) with a “buy” rating and $37 price target. The stock closed at $19.48 on Monday.

With impressive pivotal studies on solithromycin (Solitaire-IV and Solitaire-Oral), we encourage investors to accumulate a position in Cempra as the company leverages its clinical data in treating community acquired bacterial pneumonia (CABP), including the increasing number of drug-resistant strains,” writes analyst Michael Higgins.

Read More
ARIAD Pharma initiates Phase 1/2 trial in NSCLC

ARIAD Pharmaceuticals (NASDAQ:ARIA) has initiated a Phase 1/2 clinical trial of AP32788, an investigational tyrosine kinase inhibitor (TKI) designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in EGFR or HER2.

AP32788 targets tumors driven by EGFR or HER2 kinases and was designed to achieve selective inhibition of these kinases with exon 20 mutations. There are currently no approved targeted treatment options available for the approximately 4% to 9% of EGFR-mutated lung tumors with exon 20 insertion mutations in NSCLC patients.

Read More
Rodman assumes coverage of NephroGenex at neutral

Rodman & Renshaw analyst Raghuram Selvaraju has assumed coverage of NephroGenex (NASDAQ:NRX) with a “neutral” rating and without a price target. The stock was quoted at 40 cents Friday afternoon.

The board of NephroGenex decided in late February 2016 to pause the oral Pyridorin pivotal program in diabetic nephropathy, to effect a restructuring of the company’s operations and implement a strategic transaction.

Read More
Oramed gets Indian patent for oral administration of proteins

Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins” has been granted by the Indian Patent Office.

Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule, ORMD-0801. Having completed multiple Phase 2a trials, a Phase 2b trial in patients with Type 2 diabetes is ongoing under an IND with the FDA. In addition Oramed is developing an oral GLP-1 analog capsule, ORMD-0901.

Read More